The US FDA has approved Zynlonta (loncastuximab tesirine), the eleventh antibody-drug conjugate and the first for ADC Therapeutics.
Zynlonta received the thumbs up from the US Food and Drug Administration (FDA) last week for the treatment of patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
The antibody-drug conjugate (ADC) is composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD)-based cytotoxic warhead. PBDs are a class of compounds that kill cells by binding their DNA and interfering with replication. In nature they are made by a group of bacteria known as actinomycetes.
The approval is the latest milestone for developer ADC Therapeutics, which span out of UK-based Spirogen, an antibody-drug conjugate developer acquired by AstraZeneca in 2013.
Last May, the company raised $233 million through an initial public offering (IPO) with a substantial amount being used to support clinical development.
With the approval of Zynlonta coming a month ahead of the expected PDUFA date, ADC Therapeutics is now preparing to launch its first commercialized therapy.
In March, the firm laid out its commercial strategy for the ADC as part of an investor presentation. As part of this, management described how it is reliant on its contract development and manufacturing organizations (CDMOs) to support production. Among its partners, it names Avid Bioservices as producer of the antibody, Lonza for the payload, and BSP Pharmaceuticals for drug substance and drug product.
The company added it already has commercial supply in stock to support launch and beyond.
With only 11 products approved by the US FDA, ADC Therapeutics joins a small group of ADC developers. The other approved products are:
|Drug||Maker||Condition||Trade name||Approval Year|
|Gemtuzumab ozogamicin||Pfizer/Wyeth||relapsed acute myelogenous leukemia (AML)||Mylotarg||2017 (originally 2000)|
|Brentuximab vedotin||Seattle Genetics, Millennium/Takeda||relapsed HL and relapsed sALCL||Adcetris||2011|
|Trastuzumab emtansine||Genentech, Roche||HER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoid||Kadcyla||2013|
|Inotuzumab ozogamicin||Pfizer||relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia||Besponsa||2017|
|Moxetumomab pasudotox||Astrazeneca||adults with relapsed or refractoryÂ hairy cell leukemiaÂ (HCL)||Lumoxiti||2018|
|Polatuzumab vedotin-piiq||Genentech, Roche||relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)||Polivy||2019|
|Enfortumab vedotin||Astellas/Seattle Genetics||adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy||Padcev||2019|
|Trastuzumab deruxtecan||AstraZeneca/Daiichi Sankyo||adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens||Enhertu||2019|
|Sacituzumab govitecan||Immunomedics||adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease||Trodelvy||2020|
|Belantamab mafodotin-blmf||GlaxoSmithKline (GSK)||adult patients with relapsed or refractory multiple myeloma||Blenrep||2020|